L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI)

Request For Quotation
L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI) Basic information
Product Name:L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI)
Synonyms:L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI);KRAS G13D peptide, 25 mer
CAS:145019-94-9
MF:C118H201N29O36S
MW:2634.13
EINECS:
Product Categories:
Mol File:145019-94-9.mol
L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI) Structure
L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI) Chemical Properties
Boiling point 2477.0±65.0 °C(Predicted)
density 1.257±0.06 g/cm3(Predicted)
SequenceMet-Thr-Glu-Tyr-Lys-Leu-Val-Val-Val-Gly-Ala-Gly-Asp-Val-Gly-Lys-Ser-Ala-Leu-Thr-Ile-Gln-Leu-Ile-Gln
Safety Information
MSDS Information
L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI) Usage And Synthesis
UsesKRAS G13D peptide, 25 mer, a KRAS activating oncogene mutation peptide, is an immune potentiator extracted from patent WO2018144775A1. KRAS G13D peptide, 25 mer can be used to prepare KRAS vaccine[1].
References[1] Huang EYC, et, al. Immunomodulatory therapeutic mrna compositions encoding activating oncogene mutation peptides. WO2018144775A1.
L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI) Preparation Products And Raw materials
Tag:L-Glutamine, L-methionyl-L-threonyl-L-α-glutamyl-L-tyrosyl-L-lysyl-L-leucyl-L-valyl-L-valyl-L-valylglycyl-L-alanylglycyl-L-α-aspartyl-L-valylglycyl-L-lysyl-L-seryl-L-alanyl-L-leucyl-L-threonyl-L-isoleucyl-L-glutaminyl-L-leucyl-L-isoleucyl- (9CI)(145019-94-9) Related Product Information
2,7-Diazaspiro[4.4]nonane-2-acetamide, α-cyclopentyl-7-[[(2R,3R)-3-cyclopropyl-1-methyl-2-aziridinyl]carbonyl]-N-[(1R,10S,12S,18S)-1-[5-(4-cyclopropyl-1-piperazinyl)-2-[(1S)-1-methoxyethyl]-3-pyridinyl]-2,7,8,10,11,12,13,16,17,18,19,21,22,23-tetradecahydro-22,22-dimethyl-13,19-dioxo-2-(2,2,2-trifluoroethyl)-15H-3,5-etheno-14,18-imino-6,10-methano-6H-pyrrolo[3,4-g][1,12,4,18]dioxadiazacyclodocosin-12-yl]-, (αS,5S)- Y-27632 1,4-Oxazepin-5(2H)-one, 4-[3-[[2-[[2-ethyl-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-(trifluoromethyl)-4-pyrimidinyl]amino]propyl]tetrahydro- RMC6291 RMC-7977 EHT1864